A Safety and Efficacy Study of T0903131 (INT131) Besylate to Treat Type 2 Diabetes Mellitus

Inclusion Criteria: * Clinical Diagnosis of Type 2 Diabetes Mellitus for at least 3 months prior to enrollment * Fasting Plasma Glucose between 126 and 240 mg/dL * Hemoglobin-A1c (HbA1c) between 6.8% and 10.0% * Fasting C-peptide \> 0.8 ng/mL Exclusion Criteria: * Treatment with any pharmacotherapy for Type 2 Diabetes Mellitus within previous 6 weeks prior to screening * Prior treatment with Thiazolidinedione, including Troglitazone, Rosiglitazone, pioglitazone * BMI \> 42 kg/m2 * Presence of any diabetic complications requiring chronic therapy * Presence or history of any form of hepatic disease * Serum creatinine \> 1.8 mg/dL * History of cardiac arrhythmias or abnormal cardiac electrophysiology * Any reason that, in the Investigator's judgment, would have interfered with the ability of the subject to comply with the requirements of the protocol